

**MO HEALTHNET DRUG UTILIZATION REVIEW BOARD**

**April 19, 2017**

**Department of Natural Resources, La Charrette/Nightengale Conference Rm, Jefferson City MO**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Kenneth Haller, MD  
Sandra Bollinger, Pharm D  
Jennifer Passanise, FNP  
Charlene Heyde, RPh  
Ginger Nicol, MD  
Glenn Talboy, MD

**MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
Jenna McTeer, RN, Clinical Management  
Angela Wilson, Manager, Band I  
Dr. Timothy Kling, MD, Assistant Medical Director  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Mitch Ruth, Fiscal Unit Manager  
Lisa Smith, Program Development Specialist

**DUR BOARD MEMBERS ABSENT**

Stacy Mangum, Pharm D  
Kirk Nelson, MD  
Randy Beckner, Pharm D

**CONTRACTED STAFF PRESENT**

Josh Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Janella Sheen, Conduent

**OTHERS IN ATTENDANCE**

Michael Lafond, Abbvie  
Rick Kegler, Otsuka  
Robert Kile, Biogen  
Mike Holmes, Sunovion  
David Largo, Spernus  
Ashley Polce, Abbvie  
Tom Peddicord, Novartis  
Evan Rushing, Alkermes  
Steve Naert, Lilly  
Don Kempir, Novo Nordisk

Drug Utilization Review Board Minutes April 19, 2017

<b>Welcome, Introductions and Opening Remarks</b>	Susan Abdel-Rahman, Pharm D, called the meeting to order. Stephen Calloway, RPh facilitated the meeting on behalf of the MO Health Net Division (MHD). Charlene Heyde, RPh, brought three students with her and introduced them as Syed – Muhammad Zaidi, Clayton Whittington and Shelley Monroe.
<b>Minutes Review and Approval</b>	Minutes of the January 2017 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
<b>Pharmacy Program/Budget Update</b>	Stephen Calloway presented a brief PowerPoint including highlights and details of the Pharmacy Program. The presentation contained graphs representing an expenditure amount per member for all eligible participants, disabled participants, elderly participants, and other; a pie chart of participants; and expenditures by participants. The top four drug classes per FY were shared. Pharmacy expenditures were discussed, including Information on the Hepatitis C Expenditures FY 2016 thru FYTD 2017. Other program statistics were shared, along with discussion of pharmaceutical industry trends and observations. Calloway indicated MHD is working with other state agencies as part of the Prescription Drug Misuse Workgroup.
<b>Review of Prior Authorization Meeting</b>	Copies of the agenda and draft minutes from the March 2017 <i>Drug Prior Authorization Committee Meeting</i> were included in the members' meeting packet.
<b>Old Business Implementation Schedule</b>	Stephen Calloway and Mark Rouseau discussed Hepatitis C criteria for treatments. An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule included the September/October 2016 PDL classes that were implemented January 2017 and the December 2016/January 2017 PDL decisions to be implemented April 2017. Pending ratification, PDL decisions from the March 2017 Drug PA Committee meeting will be implemented July 2017. Schedules may be found on the MHD web page at: <a href="http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf</a>
<b>New Drug Review</b>	<p>Stephen Calloway reviewed the new drug products that were identified for the quarter January, February and March 2017, the recommended status within the clinical program.</p> <ul style="list-style-type: none"> <li>• <b>Discussion</b> - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions.</li> <li>• <b>Decision</b> - The listing and recommendations were approved as part of a block vote by the DUR Board (See Roll Call Votes).</li> </ul>

<b>Clinical Edits</b>	
None	
<b>Preferred Drug List (PDL) Annual Review</b>	
<b>Topical Benzoyl Peroxide/Clindamycin Combination</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> — Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Beta Adrenergic Agents - Nebulized</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>COPD Anticholinergic Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Cough and Cold Preparations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Herpes Antivirals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Inhaled Antibiotic Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Inhaled Oral Corticosteroids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> — Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Intranasal Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Intranasal Steroids and Allergy Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Leukotriene Modifiers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>2<sup>nd</sup> Generation Antihistamines</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>2<sup>nd</sup> Generation Antihistamines/Decongestant</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ophthalmic Antihistamines and Allergy Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ophthalmic Mast</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ophthalmic Mast Cell Stabilizers</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ophthalmic Nonsteroidal Anti-Inflammatory Drugs</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ophthalmic Prostaglandin Agonists</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ophthalmic Fluoroquinolones</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Oral Antipsoriasis Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antifungal (Onychomycosis) Agents - Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Otic Fluoroquinolones</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>Pancreatic Enzyme Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Self – Injectable Epinephrine Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Agents for Actinic Keratosis</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Agents for Psoriasis</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Androgenic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Antifungal Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Antiparasitic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Antiviral Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Immunomodulators</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Retinoids</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Topical Steroids</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>Ulcerative Colitis - Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Ulcerative Colitis - Rectal</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
	A handout of therapeutic categories scheduled for Annual Review and Renewal on the Preferred Drug List at the March/April Advisory meetings was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.

<b>Conduent Update</b>	Luke Boehmer, Pharm D reviewed clinical edits. Katie Wilbers, Pharm D, discussed DUR.
<b>Top 25 Drugs by Cost</b>	Dr. Boehmer reviewed the Top 25 Drugs Summary Reports for the 3 <sup>rd</sup> quarter 2015 through the 2 <sup>nd</sup> quarter 2016. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
<b>Call Center Statistics Clinical Edit Summary Report</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Dr. Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess. Board members were also updated on approved, denied, and total Prior Authorizations for New Drugs in August and September 2016, as well as PA transaction counts by PDL and Clinical Edit.
<b>Drug Utilization Review Activities</b>	Dr. Boehmer presented Claims, Spend, and Call Center statistics for the COPD agents, Short Acting Beta Agonist, Long Acting Beta Agonist, Inhaled Corticosteroids, and Nebulized Beta Agonist at the March/April PA and DUR meetings. Katie Wilbers presented Year over year Antibiotic Overutilization Outcomes – Assessment shows continued decreasing trend in broad spectrum antibiotic use which is a positive outcome. Migraine Therapy Outcomes – Assessment showed a decrease in participants hitting clinical indicators in both target and control group and a total 6-month savings of \$8,537.76. Presented the abstract Conduent co-authored with MHD on compounding.
<b>Adjourn</b>	Ginger Nicol, MD made a motion to move to close this meeting under Section 610.021(14), (5) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for July 19, 2017.

**Roll Call Votes – April 19, 2017**

<b>MEMBER</b>	<b>MEETING MINUTES</b>	<b>ALL RECOMMENDATIONS BLOCK VOTE</b>	<b>CLOSED SESSION</b>
Susan Abdel-Rahman, Pharm D	Y	Y	Y
Charlene Heyde, RPh	SY	SY	SY
Sandra Bollinger, Pharm D	MY	Y	Y
Kenneth Haller, MD	Y	Y	Y
Glenn Talboy, MD	Y	Y	Y
Jennifer Passanise, FNP	Y	Y	Y
Stacy Mangum, Pharm D	-	-	-
Kirk Nelson, MD	-	-	-
Ginger Nicol, MD	Y	MY	MY
Randy Beckner, Pharm D	-	-	-

**EXECUTIVE SESSION**  
**April 19, 2017**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Kenneth Haller, MD  
Sandra Bollinger, Pharm D  
Jennifer Passanise, FNP  
Charlene Heyde, RPh  
Ginger Nicol, MD  
Glen Talboy, MD

**DUR BOARD MEMBERS ABSENT**

Kirk Nelson, MD  
Randy Beckner, Pharm D  
Stacy Mangum, Pharm D

**MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
Jenna McTeer, RN, Clinical Management  
Angela Wilson, Manager Band I  
Timothy Kling, MD, Assistant Medical Director EBU  
Franki Moseley, Administrative Office Support Assistant  
Elizabeth Short, Medicaid Specialist  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Fiscal Unit Manager

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Janella Sheen, Conduent

Minutes Review	Minutes of the April Executive Session were approved as submitted.
Case Reviews	Jenna McTeer, RN reviewed 1 case.
Adjourn	Executive session adjourned.